The Middle East & Africa upstream bioprocessing market was valued at US$ 275.22 million in 2022 and is expected to reach US$ 712.66 million by 2030; it is estimated to grow at a CAGR of 12.6% from 2022 to 2030.
According to Culture Biosciences, the money has been used to treble the capacity of bioreactors as well as to develop more cloud-based software monitoring and development tools for biomanufacturing research and development. The company states that this investment will help scientists manage their whole R&D workflow via software applications, hence supporting the digitization of biomanufacturing R&D.
As R&D investments continue to surge, particularly in novel biologics, advanced therapies, and personalized medicine, there is a parallel emphasis on optimizing upstream bioprocessing technologies and methodologies. This trend is leading to the development of innovative bioreactor systems, cell culture media formulations, and process automation solutions to enhance the efficiency, scalability, and productivity of biopharmaceutical production operations.
Furthermore, the focus on R&D investments favors the development of cutting-edge bioprocessing platforms that cater to the evolving landscape of biopharmaceuticals, including next-generation therapeutic modalities and biosimilars. Additionally, dedicating R&D funds for bioprocessing trends such as continuous bioprocessing and advanced analytics for process monitoring is expected to reshape the future of upstream bioprocessing, driving the adoption of state-of-the-art technologies and establishing new benchmarks for process performance, quality, and regulatory compliance.
Increasing Investments in R&D in Biopharmaceutical Industry Bolster Middle East & Africa Upstream Bioprocessing Market
Increasing investments in research and development (R&D) in the biopharmaceutical industry are likely to bring new trends into the upstream bioprocessing market in the coming years. In March 2020, Culture Biosciences announced securing the funds of US$ 15 million (13.4 million) in the Series A investment round, citing the backing of new and existing venture capital backers.According to Culture Biosciences, the money has been used to treble the capacity of bioreactors as well as to develop more cloud-based software monitoring and development tools for biomanufacturing research and development. The company states that this investment will help scientists manage their whole R&D workflow via software applications, hence supporting the digitization of biomanufacturing R&D.
As R&D investments continue to surge, particularly in novel biologics, advanced therapies, and personalized medicine, there is a parallel emphasis on optimizing upstream bioprocessing technologies and methodologies. This trend is leading to the development of innovative bioreactor systems, cell culture media formulations, and process automation solutions to enhance the efficiency, scalability, and productivity of biopharmaceutical production operations.
Furthermore, the focus on R&D investments favors the development of cutting-edge bioprocessing platforms that cater to the evolving landscape of biopharmaceuticals, including next-generation therapeutic modalities and biosimilars. Additionally, dedicating R&D funds for bioprocessing trends such as continuous bioprocessing and advanced analytics for process monitoring is expected to reshape the future of upstream bioprocessing, driving the adoption of state-of-the-art technologies and establishing new benchmarks for process performance, quality, and regulatory compliance.
Middle East & Africa Upstream Bioprocessing Market Overview
The Middle East & Africa upstream bioprocessing market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The UAE is the largest market for upstream bioprocessing. The market is driven by extensive research projects undertaken by several research institutes, and the availability of infrastructure and facilities for fundamental as well as advanced research, particularly in the UAE and Saudi Arabia.Middle East & Africa Upstream Bioprocessing Market Segmentation
- The Middle East & Africa upstream bioprocessing market is segmented based on product type, workflow, usage type, mode, and country. Based on product type, the Middle East & Africa upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The cell culture services held the largest market share in 2022.
- Based on workflow, the Middle East & Africa upstream bioprocessing market is categorized into media preparation, cell culture, and cell separation. The cell separation held the largest market share in 2022.
- Based on usage type, the Middle East & Africa upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use held a larger market share in 2022
- Based on mode, the Middle East & Africa upstream bioprocessing market is bifurcated into in-house and outsourced. The outsourced held a larger market share in 2022.
- Based on country, the Middle East & Africa upstream bioprocessing market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa upstream bioprocessing market share in 2022.
- Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, and Corning Inc are some of the leading companies operating in the Middle East & Africa upstream bioprocessing market.
Market Highlights
- Based on product type, the Middle East & Africa upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.6% market share in 2022, amassing US$ 97.87 million. It is projected to garner US$ 248.67 million by 2030 to expand at 12.4% CAGR during 2022-2030.
- The cell separation segment held 44.4% share of Middle East & Africa upstream bioprocessing market in 2022, amassing US$ 122.16 million. It is projected to garner US$ 325.53 million by 2030 to expand at 13.0% CAGR during 2022-2030.
- The single-use segment held 55.5% share of Middle East & Africa upstream bioprocessing market in 2022, amassing US$ 152.64 million. It is projected to garner US$ 402.12 million by 2030 to expand at 12.9% CAGR during 2022-2030.
- In terms of mode, the Middle East & Africa upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house segment held 63.9% share of Middle East & Africa upstream bioprocessing market in 2022, amassing US$ 175.84 million. It is projected to garner US$ 447.49 million by 2030 to expand at 12.4% CAGR during 2022-2030.
- This analysis states that Saudi Arabia captured 34.6% share of Middle East & Africa upstream bioprocessing market in 2022. It was assessed at US$ 95.12 million in 2022 and is likely to hit US$ 249.61 million by 2030, exhibiting a CAGR of 12.8% during 2022-2030.
- In January 2023, Sartorius collaborated with RoosterBio Inc to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based exosome production platform that delivers industry-leading yield, purity, and potency.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa upstream bioprocessing market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa upstream bioprocessing market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Middle East & Africa Upstream Bioprocessing Market Landscape
5. Middle East & Africa Upstream Bioprocessing Market - Key Market Dynamics
7. Middle East & Africa Upstream Bioprocessing Market Analysis - by Product Type
8. Middle East & Africa Upstream Bioprocessing Market Analysis - by Workflow
9. Middle East & Africa Upstream Bioprocessing Market Analysis - by Usage Type
10. Middle East & Africa Upstream Bioprocessing Market Analysis - by Mode
11. Middle East & Africa Upstream Bioprocessing Market - Country Analysis
12. Industry Landscape
13. Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned
Some of the leading companies in the Middle East and Africa Upstream Bioprocessing market include:- Thermo Fisher Scientific Inc
- Esco Micro Pte Ltd
- Sartorius AG
- Danaher Corp
- Getinge AB
- Merck KGaA
- Corning Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 117 |
| Published | August 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 275.22 Million |
| Forecasted Market Value ( USD | $ 712.66 Million |
| Compound Annual Growth Rate | 12.6% |
| Regions Covered | Africa, Middle East |
| No. of Companies Mentioned | 8 |
